Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3%
Nautilus Biotechnology established a new at-the-market (ATM) Sales Agreement with TD Cowen to sell up to $125 million of common stock, while simultaneously terminating its February 28, 2024 ATM agreement with the same counterparty. The new program allows Nautilus to direct timing, size, and pricing…